Joseph Renzulli, MD, FACS
Associate Professor of UrologyCards
Additional Titles
Chief of Urology at Lawrence + Memorial Hospital, Urology, Lawrence + Memorial Hospital
Chief of Urology at Westerly Hospital, Urology, Westerly Hospital
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief of Urology at Lawrence + Memorial Hospital, Urology, Lawrence + Memorial Hospital
Chief of Urology at Westerly Hospital, Urology, Westerly Hospital
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Chief of Urology at Lawrence + Memorial Hospital, Urology, Lawrence + Memorial Hospital
Chief of Urology at Westerly Hospital, Urology, Westerly Hospital
Contact Info
About
Titles
Associate Professor of Urology
Positions outside Yale
Chief of Urology at Lawrence + Memorial Hospital, Urology, Lawrence + Memorial Hospital; Chief of Urology at Westerly Hospital, Urology, Westerly Hospital
Biography
Dr. Joseph Renzulli offers his patients laparoscopic, robotic, and other minimally invasive techniques for treating urologic cancers, including prostate, kidney, bladder, and testicular cancers. A large focus of his practice is on men’s health, including a special interest in the diagnosis and medical and surgical treatment of prostate cancer. He is actively involved as primary investigator in multiple prostate cancer clinical trials.
Dr. Renzulli received his undergraduate degree Magna Cum Laude in Biology from Boston University, and his medical degree from Boston University School of Medicine. He completed his residency training at Yale School of Medicine before joining The Miriam Hospital and The Alpert Medical School of Brown University.
He is the Eastern Regional Director of Urology for Yale Medicine and Chief of Urology at both Lawrence + Memorial Hospital and Westerly Hospital.
Appointments
Urology
Associate Professor on TermPrimary
Other Departments & Organizations
- Prostate & Urologic Cancers Program
- Urologic Oncology
- Urology
- Yale Cancer Center
- Yale Medicine
Education & Training
- Chief Resident
- Yale School of Medicine (2006)
- Resident
- Yale School of Medicine (2005)
- Internship
- Yale School of Medicine (2002)
- MD
- Boston University School of Medicine (2001)
- BA
- Boston University, Biology (1997)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Joseph Brito III, MD
Katherine Rotker, MD
Michael S. Leapman, MD, MHS
Preston C. Sprenkle, MD
Timothy Tran, MD
Ankur Choksi, MD
Publications
2024
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.Peer-Reviewed Original ResearchConceptsMRI-TRUSMRI-TRUS fusionImage-guided biopsyFusion biopsyGG upgradingTRUS biopsyBiopsy strategyBiopsy typeNo significant differencePathological concordanceBiopsy techniqueHigh-resolution micro-ultrasoundMRI-TRUS fusion biopsyMultivariate logistic-regression analysisMRI fusion biopsySystematic transrectal ultrasoundProstate cancer patientsSignificant differenceMicro-ultrasoundLogistic-regression analysisMultivariable-analysisPathological downgradingPathological upgradingRandomized controlled trialsProstate biopsy
2023
Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life
Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolazco J, Washington S, Renzulli J, Sprenkle P, Kim I, Leapman M. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. Urologic Oncology Seminars And Original Investigations 2023, 42: 28.e9-28.e20. PMID: 38161105, DOI: 10.1016/j.urolonc.2023.10.005.Peer-Reviewed Original ResearchConceptsLethal prostate cancerSociodemographic factorsAdvanced CaPAdvanced diseaseYounger patientsProstate cancerHigher oddsAdvanced stageProstate-specific antigen (PSA) screeningCharacteristics of patientsNational Cancer DatabaseRetrospective cohort studySubset of patientsPatient sociodemographic factorsMultivariable logistic regressionPatients' health insuranceHighest income quartileCohort studyAdvanced cancerAntigen screeningMean ageInsurance statusCancer DatabaseCaP screeningSociodemographic disparities
2021
MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT
Shore N, Renzulli J, Fleshner N, Hollowell C, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg M, Tomlins S. MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT. Journal Of Urology 2021, 206: e1099-e1099. DOI: 10.1097/ju.0000000000002102.17.Peer-Reviewed Original Research
2020
A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).
Ross A, Armstrong A, Pieczonka C, Bailen J, Tutrone R, Cooperberg M, Pavlovich C, Renzulli J, Haynes H, Sheikh N, Shore N. A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2020, 38: 321-321. DOI: 10.1200/jco.2020.38.6_suppl.321.Peer-Reviewed Original ResearchConceptsMetastatic castrate-resistant prostate cancerCD54 upregulationProstate cancerOverall survivalActive surveillanceCell countCastrate-resistant prostate cancerPeripheral blood mononuclear cellsEarly-stage prostate cancerAutologous cellular immunotherapyLarger immune responsesPhase III studyBlood mononuclear cellsStage prostate cancerTotal nucleated cell countNucleated cell countIII studyCellular immunotherapyMononuclear cellsTreatment weekProstate adenocarcinomaT cellsImmune responseTNC countProvent
2018
PD52-03 THE ASSOCIATION OF EDUCATION LEVEL WITH THE UTILIZATION OF SHARED DECISION MAKING IN PROSTATE CANCER SCREENING
Pereira J, Gershman B, Renzulli J. PD52-03 THE ASSOCIATION OF EDUCATION LEVEL WITH THE UTILIZATION OF SHARED DECISION MAKING IN PROSTATE CANCER SCREENING. Journal Of Urology 2018, 199: e981-e982. DOI: 10.1016/j.juro.2018.02.2355.Peer-Reviewed Original Research
2017
MP92-19 NOVEL, NONTOXIC SKIN CARE FORMULATION ASSOCIATED WITH LOWER CAUTI RATES FOR HIGH-RISK ICU, NEURO, C-V AND TRAUMA PATIENTS WHEN USED FOR FOLEY CATHETER INSERTION AND MAINTENANCE
Turini G, Renzulli J. MP92-19 NOVEL, NONTOXIC SKIN CARE FORMULATION ASSOCIATED WITH LOWER CAUTI RATES FOR HIGH-RISK ICU, NEURO, C-V AND TRAUMA PATIENTS WHEN USED FOR FOLEY CATHETER INSERTION AND MAINTENANCE. Journal Of Urology 2017, 197: e1235. DOI: 10.1016/j.juro.2017.02.2880.Peer-Reviewed Original ResearchMP97-13 ASSOCIATION OF EXTENDED PELVIC LYMPH NODE DISSECTION WITH THROMBOEMBOLIC EVENTS AND LYMPHOCELE FORMATION AMONG MEN UNDERGOING ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY WITH PELVIC LYMPH NODE DISSECTION
Pereira J, Shillan H, Tucci C, Pareek G, Golijanin D, Gershman B, Renzulli J. MP97-13 ASSOCIATION OF EXTENDED PELVIC LYMPH NODE DISSECTION WITH THROMBOEMBOLIC EVENTS AND LYMPHOCELE FORMATION AMONG MEN UNDERGOING ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY WITH PELVIC LYMPH NODE DISSECTION. Journal Of Urology 2017, 197: e1308. DOI: 10.1016/j.juro.2017.02.3057.Peer-Reviewed Original ResearchMP14-05 THE ASSOCIATION OF AGE WITH PERIOPERATIVE MORBIDITY AND MORTALITY AMONG PATIENTS UNDERGOING RADICAL PROSTATECTOMY
Pereira J, Pareek G, Golijanin D, Renzulli J, Gershman B. MP14-05 THE ASSOCIATION OF AGE WITH PERIOPERATIVE MORBIDITY AND MORTALITY AMONG PATIENTS UNDERGOING RADICAL PROSTATECTOMY. Journal Of Urology 2017, 197: e163-e164. DOI: 10.1016/j.juro.2017.02.469.Peer-Reviewed Original Research781 Perioperative morbidity of open versus minimally invasive partial nephrectomy: A contemporary analysis of the National Surgical Quality Improvement Program (NSQIP)
Pereira J, Renzulli J, Pareek G, Moreira D, Golijanin D, Gershman B. 781 Perioperative morbidity of open versus minimally invasive partial nephrectomy: A contemporary analysis of the National Surgical Quality Improvement Program (NSQIP). European Urology Open Science 2017, 16: e1352-e1353. DOI: 10.1016/s1569-9056(17)30834-5.Peer-Reviewed Original Research
2016
The Role of a Standardized Clinical Care Pathway in Patient Satisfaction and Quality of Life Outcomes after Robotic Assisted Laparoscopic Radical Prostatectomy
Turini G, Clark M, Machan J, Tucci C, Renzulli J. The Role of a Standardized Clinical Care Pathway in Patient Satisfaction and Quality of Life Outcomes after Robotic Assisted Laparoscopic Radical Prostatectomy. Urology Practice 2016, 4: 232-238. PMID: 37592643, DOI: 10.1016/j.urpr.2016.06.006.Peer-Reviewed Original ResearchConceptsLaparoscopic radical prostatectomyStandardized care pathwayClinical care pathwayLength of stayRadical prostatectomyCare pathwayPatient satisfactionPostoperative lengthChart reviewEmergency departmentUrology officeStandardized clinical care pathwayRetrospective chart reviewOverall patient satisfactionPostoperative patient careCohort of menQuality of careLAPAROSCOPIC RADICALPathway cohortPostoperative callsReadmission ratesEarly dischargeHospital readmissionPostoperative qualitySame surgery
Clinical Trials
Current Trials
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
HIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2024Recruiting ParticipantsGenderMaleAge18+ years
Clinical Care
Overview
Joseph F. Renzulli II MD, FACS, is a Yale Medicine urologist who has expertise in robotic-assisted and laparoscopic surgeries for treating urologic cancers such as prostate, bladder, and kidney cancer.
“The best part of my job is being able to offer patients cutting-edge surgical therapies right here in their own community,” Dr. Renzulli says, “so that they do not have to travel to distant medical centers and be away from their loved ones during their most stressful times.” For him, medicine is a calling. “Being able to help people in their most vulnerable times is something that I have always seen as an amazing responsibility, and I am privileged to be able to care for them,” he says. After a cancer diagnosis, Dr. Renzulli develops individualized treatment plans for his patients, which may include helping them find and enroll in open clinical trials. He also tries to ease anxiety.
“I tell patients to let me do the worrying for them. I have seen their situation before and can take care of it for them,” he says.
Clinical Specialties
Fact Sheets
Jelmyto®
Learn More on Yale MedicineMinimally Invasive Reproductive Surgery
Learn More on Yale MedicineUroLift
Learn More on Yale MedicineProstate Cancer
Learn More on Yale Medicine
Board Certifications
Urology
- Certification Organization
- AB of Urology
- Original Certification Date
- 2008
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- January 16, 2025
Yale Urology Research [Q4: October-December 2024]
- October 30, 2024
Yale Urology Research [Q3: July-September 2024]
- August 05, 2024
When It Comes To Robotic Surgery, The Future Is Now – And Tomorrow
- July 31, 2024
Yale Urology Research [Q2: April-June 2024]
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.